Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717008 | 0.91 | RAB9A (0.37) | RAB9ASMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL13717004 | 0.91 | RAB9A (0.37) | RAB9ASMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL13820215 | 0.87 | RAB9A (0.35) | RAB9ASMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL13820149 | 0.87 | ROCK2 (0.34) | MEN1KMT2AROCK2ROCK1MYLK4 | |
| SCHEMBL13820137 | 0.85 | RAB9A (0.33) | RAB9ASMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL13820141 | 0.85 | LTA4H (0.42) | — | |
| SCHEMBL13820171 | 0.81 | LTA4H (0.45) | RAB9ASMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL13827713 | 0.80 | PDF (0.42) | MEN1KMT2A | |
| SCHEMBL13717193 | 0.80 | PDF (0.42) | MEN1KMT2A | |
| SCHEMBL13717190 | 0.80 | PDF (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927728-B2 | Dipeptide acetylene conjugates and a method for photocleavage of double strand DNA by dipeptide acetylene conjugates | The Florida State University Research Foundation, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120288940-A1 | DIPEPTIDE ACETYLENE CONJUGATES AND A METHOD FOR PHOTOCLEAVAGE OF DOUBLE STRAND DNA BY DIPEPTIDE ACETYLENE CONJUGATES | The Florida State University Research Foundation, Inc. (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288940-A1 | DIPEPTIDE ACETYLENE CONJUGATES AND A METHOD FOR PHOTOCLEAVAGE OF DOUBLE STRAND DNA BY DIPEPTIDE ACETYLENE CONJUGATES | DNPEP, DCLRE1A, PCNA | RAB9A 4352/4885SMN1; SMN2 4556/4885KDM4E 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.